(Q53189803)

12 May 2018

title

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. (English)

1 reference

12 May 2018

main subject

phase II clinical trial

0 references

author name string

Takashi Kobayashi

1

1 reference

12 May 2018

Tomonobu Koizumi

2

1 reference

12 May 2018

Toshihide Agatsuma

3

1 reference

12 May 2018

Masanori Yasuo

4

1 reference

12 May 2018

Kenji Tsushima

5

1 reference

12 May 2018

Keishi Kubo

6

1 reference

12 May 2018

Seiichiro Eda

7

1 reference

12 May 2018

Hiroshi Kuraishi

8

1 reference

12 May 2018

Shigeru Koyama

9

1 reference

12 May 2018

Tsutomu Hachiya

10

1 reference

12 May 2018

Nariaki Ohura

11

1 reference

12 May 2018

publication date

26 January 2012

1 reference

12 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

12 May 2018

volume

69

1 reference

12 May 2018

issue

5

1 reference

12 May 2018

page(s)

1241-1246

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1007/s00280-012-1831-0

exact match

0 references

cites work

Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1831-0

10.1007/S00280-012-1831-0

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

release_2pn6ef7afnhatljkevhfylph3u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2pn6ef7afnhatljkevhfylph3u

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22278730

1 reference

12 May 2018